



**Samuel Antwi, Ph.D., M.P.H., Mayo Clinic**

Dr. Antwi is an Assistant Professor of Epidemiology in the Mayo Clinic College of Medicine and Science, and Associate Consultant in the Department of Health Sciences Research at Mayo Clinic. His research is focused on understanding the molecular, genetic, and epigenetic factors associated with liver cancer and pancreatic cancer development, and involves integrating rigorous epidemiological methods with clinical and high-throughput genomic data to elucidate the molecular processes that underlie cancer susceptibility. A keen focus of Dr. Antwi's research is to analyze and interpret data in a biologically meaningful way, toward practical actions that will benefit patients and populations. Dr. Antwi received his Ph.D. in Epidemiology from the University of South Carolina, M.P.H. in Epidemiology from the University of Kentucky, and was a post-doctoral fellow in the NCI-funded R25 Training Program in Cancer Genetic and Genomic Epidemiology at Mayo Clinic in Rochester, MN.



**Shine Chang, Ph.D., M.S.P.H., University of Texas MD Anderson Cancer Center**

At University of Texas MD Anderson Cancer Center, Dr. Chang serves as director of the Cancer Prevention Research Training Program (CP RTP), and is a University of Texas System Distinguished Teaching Professor and tenured Ashbel Smith Professor in the Department of Epidemiology. For nearly 30 years, the CP RTP has been a multidisciplinary research training program supported by federal, state, and donor-sponsored funds, and annually prepares nearly 35 trainees, from undergraduates to postdoctoral fellows, for careers in cancer prevention and control. As a cancer epidemiologist, Dr. Chang conducts research on bio-behavioral determinants of excess body weight and weight change as cancer risk factors and on the contributors to the unequal burden of cancer of vulnerable populations. From 2017 to 2020, she led as protocol PI The University of Texas MD Anderson Cancer Center's "Mano a Mano" Mexican American Cohort Study, a prospective cohort study of more than 26,000 residents within the Houston metropolitan area that started in 2001; she continues today as MAC Special Advisor, focused on research projects. She is a fellow of The Obesity Society, a fellow of the American Association for Cancer Education, and has been recognized for excellence in mentoring and for her efforts to diversify and support the faculty, locally and nationally.



**A. Heather Eliassen, Sc.D., S.M., Harvard Medical School and Harvard T.H. Chan School of Public Health**

Dr. Heather Eliassen is an Associate Professor of Medicine and Epidemiology at Harvard Medical School and the Harvard T.H. Chan School of Public Health. She serves as co-PI of the Nurses' Health Study and the Nurses' Health Study II. She also is Director of the BWH/Harvard Cohorts Biorepository, which houses more than three million biospecimens from 200,000 cohort participants, and co-leads the Cancer Epidemiology Program at the Dana-Farber/Harvard Cancer Center. Dr. Eliassen received her B.A. from Dartmouth College, and her S.M. and Sc.D. in epidemiology from Harvard. Her research is focused on the etiology of breast cancer, examining associations between lifestyle factors, biomarkers of lifestyle and hormones, and breast cancer risk. The goal of her research is to identify ways in which women can reduce their risk of breast cancer. Dr. Eliassen participates in several ongoing cohort consortium projects, and previously led the pooled analysis of circulating carotenoids and subsequent breast cancer risk.



**Joanne Elena, Ph.D., M.P.H., National Cancer Institute, Division of Cancer Control and Population Sciences**

Dr. Joanne Elena is an epidemiologist and program director in the Clinical and Translational Epidemiology Branch of the Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute. She is responsible for developing, managing, and promoting a research portfolio of grants focused on diet and lifestyle factors that influence cancer progression, recurrence and survival, and the development of subsequent cancers. She is also involved in optimizing the use and design of cohort studies, incorporating new technologies to assess exposures and outcomes, maximizing the use of existing data, and managing several funding announcements to support large cohort studies. Dr. Elena completed her Ph.D. in nutritional epidemiology at the University of North Carolina at Chapel Hill and her M.P.H. at the Johns Hopkins Bloomberg School of Public Health.



**Marc Gunter, Ph.D., International Agency for Research on Cancer, France**

Dr. Marc Gunter is Head of the Section of Nutrition and Metabolism at the International Agency for Research on Cancer (IARC), the specialized cancer research agency of the World Health Organization. Dr. Gunter holds a Ph.D. in molecular epidemiology from the University of Cambridge and a degree in biochemistry from the University of Oxford. He completed his postdoctoral training at the U.S. National Cancer Institute and has held faculty positions at Albert Einstein College of Medicine in New York and Imperial College London. Dr. Gunter's research focuses on the role of nutrition, diabetes, and obesity in the natural history of cancer with an emphasis on metabolic dysfunction and in particular the insulin/IGF/mTOR pathway.

He is principal investigator of several studies applying high dimensional metabolic profiling within the framework of large prospective and clinical cohorts, as well as intervention studies, to identify novel biochemical pathways involved in cancer development and prognosis. Recent publications include investigations of obesity subtypes defined by metabolic measurements in relation to breast and colorectal cancer risk, adipose tissue-derived factors and breast cancer and the role of endogenous estrogens in colorectal cancer development. In addition to his current role as co-principal investigator of the European Prospective Investigation into Cancer (EPIC) study, which represents a network of 23 collaborating centres spanning 10 European countries and 520,000 individuals, he is actively involved in various consortia, including the Consortium of Metabolomics Studies (COMETS) and the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO). He is currently leading a large-scale investigation on diabetes and cancer within the NCI Cohort Consortium, which comprises the analysis of data from more than 30 prospective cohort studies and 3 million individuals.



**Nonye Harvey, Dr.P.H., M.P.H., National Cancer Institute, Division of Cancer Control and Population Sciences**

Dr. Nonye Harvey is a Program Director in the Office of the Associate Director of the Epidemiology and Genomics Research Program (EGRP), Division of Cancer Control and Population Sciences (DCCPS) at the NCI. She is also the team lead for EGRP planning and budget, and leads program-wide efforts on data sharing policy and implementation, evaluation, scientific initiative, and strategic planning. She has served as the Executive Director of [NCI Cohort Consortium](#) since 2006, and has actively participated in and co-authored several peer-reviewed publications on consortium pooling studies. Dr. Harvey has also been involved in the development and management of

cancer epidemiology cohort research and consortia, including the Breast Cancer and Environment Research Program initiative. Prior to joining EGRP, she worked in the NCI Office of Cancer Survivorship in DCCPS and managed the Mid-Atlantic Region Pediatric Environmental Health Specialty Unit at the George Washington University (GWU) Milken Institute School of Public Health where she worked on children's environmental health research and provider training programs. She earned her M.P.H. in maternal and child health and international health from the GWU Milken Institute School of Public Health and her Dr.P.H. in leadership in public health from the University of Illinois at Chicago School of Public Health.



**Kathy Helzlsouer, M.D., M.H.S., National Cancer Institute, Division of Cancer Control and Population Sciences**

Dr. Kathy Helzlsouer serves as Associate Director of the Epidemiology and Genomics Research Program and chief medical officer for the National Cancer Institute's (NCI) Division of Cancer Control and Population Sciences. Dr. Helzlsouer is board certified in internal medicine and medical oncology. She earned her medical degree from the University of Pittsburgh and has received postgraduate education and training in internal medicine, oncology, and epidemiology at the University of Virginia and the Johns Hopkins University. Prior to joining NCI, Dr. Helzlsouer was a professor in the Department of Epidemiology at the Johns Hopkins University Bloomberg School of Public Health and established the Prevention and Research Center at an academic community hospital. Dr. Helzlsouer's research experience and clinical activities include cancer epidemiology and prevention, cancer risk assessment, cancer survivorship, cohort studies, and clinical trials.



**Hazel Nichols, Ph.D., S.M., University of North Carolina Gillings School of Global Public Health**

Dr. Nichols is an Associate Professor of Epidemiology at the UNC Gillings School of Global Public Health. She received her B.S. from Tulane University, S.M. from Harvard University, and doctorate from Johns Hopkins University. She was a Research Fellow in the NIEHS Epidemiology Branch where she currently collaborates on ongoing studies of long-term health after a breast cancer diagnosis. She is a founding member of the Premenopausal Breast Cancer Collaborative Group and has been an active participant in the NCI Cohort Consortium since 2013. Her recent work addresses the intersection of cancer and pregnancy across the lifespan, including pregnancy characteristics and breast cancer risk in young women, and pregnancy outcomes after adolescent

and young adult cancer. In addition to the Sister Study and the NCI Cohort Consortium, her research is based within the Cancer Research Network (a consortia of U.S. healthcare systems) and statewide cancer registry linkage studies in North Carolina and other states. She is an active member of the American Society of Preventive Oncology and former chair of the Early Career Special Interest Group.



**Katie O'Brien, Ph.D., M.S.P.H., National Institute of Environmental Health Sciences**

Katie M. O'Brien, Ph.D., is a staff scientist in the Epidemiology Branch, where she helps lead the Sister Study, a study of environmental and genetic risk factors for breast cancer. Dr. O'Brien is personally interested in studying modifiable risk factors for reproductive-related cancers, including personal care products, hormonal factors, and biomarkers of environmental exposures. She is active in both the Premenopausal Breast Cancer Collaborative Group and the Ovarian Cancer Cohort Consortium.

Dr. O'Brien received her B.A. in mathematics and psychology from Williams College and her M.S.P.H. and Ph.D. in epidemiology from the University of North Carolina at Chapel Hill.



**Camille Pottinger, M.P.H., The Scientific Consulting Group, Inc.**

Ms. Pottinger is a research associate at The Scientific Consulting Group, Inc. (SCG). In this role, she works with staff in the Epidemiology and Genomics Research Program (EGRP) at the National Cancer Institute (NCI) to provide administrative and programmatic support for the NCI Cohort Consortium. Ms. Pottinger contributes to other EGRP initiatives such as the Cancer in Hispanics Working Group, in which she supports activities for more collaborative cancer epidemiologic research in U.S. Hispanic/Latino populations. Prior to joining SCG, Ms. Pottinger was a

Cancer Research Training Fellow at NCI where she helped with coordination, planning, and analysis of NCI Cohort Consortium activities as well as a variety of other NCI and EGRP programmatic and scientific initiatives. Ms. Pottinger received her M.P.H. in epidemiology of microbial diseases from the Yale School of Public Health and is currently pursuing her Doctor of Public Health degree at Morgan State University. Her areas of interest include cancer epidemiologic outcomes in minority populations, public health strategic leadership, and data sharing.



**Erika Rees-Punia, Ph.D., M.P.H., American Cancer Society**

As a principal scientist at the American Cancer Society, Erika Rees-Punia, Ph.D., M.P.H., leads research projects on the promotion and benefits of physical activity. She is an exercise physiologist by training, with research interests more broadly in the behavioral sciences. Dr. Rees-Punia co-manages the CPS-3 Accelerometry Sub-Study, an ongoing project that's collecting objectively measured physical activity on 20,000 participants via activity monitors. She also co-leads the American Cancer Society (ACS) Health Equity workgroup, whose goal is to identify and improve cancer health disparities. Dr. Rees-Punia is a former American Cancer Society post-doctoral fellow and National Cancer Institute intern. She received her Ph.D. in Exercise Physiology from the University of Georgia and her M.P.H. in Environmental Health from Emory University.



**Jeannette Schenk, Ph.D., M.S., Fred Hutchinson Cancer Research Center**

Dr. Jeannette M. Schenk is a Senior Staff Scientist in the Cancer Prevention Program at the Fred Hutchinson Cancer Research Center (FHCRC). She received a B.S. in molecular biology from University of California San Diego, a M.S. in clinical nutrition from New York University, and a Ph.D. in epidemiology from University of Washington. Dr. Schenk's research is focused on the associations of diet, obesity, lifestyle, and metabolic biomarkers with prostate cancer incidence and progression. She has extensive experience working with clinical and biologic data from large multi-center prostate cancer cohorts, and currently serves as Co-Investigator on two UM1 grants for the Prostate Cancer Prevention Trial (PCPT) and Selenium and Vitamin E Cancer Trial (SELECT) cohorts, and the recently funded Prostate Cancer Active Surveillance Study (PASS) cohort. In this capacity, she has collaborated on additional consortia projects, the Pooling Project of Prospective Studies of Diet and Cancer (DCPP), and the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group, which are focused on investigating associations of dietary, anthropometric factors, endogenous sex hormones, insulin-like growth factors, and nutritional biomarkers with prostate cancer risk.



**Minouk Schoemaker, Ph.D., M.S., The Institute of Cancer Research London**

Dr. Schoemaker is a researcher funded by the charity Breast Cancer Now. Most of her work is based on the Generations Study, a prospective study including over 110,000 women in the UK, with several rounds of questionnaire-data and availability of blood samples at recruitment. Her interests are primarily related to risk factors for breast cancer, including lifestyle, hormonal, and reproductive factors and mammographic density.

Dr. Schoemaker is co-leading the Premenopausal Breast Cancer Collaborative Group, an international collaboration of 22 cohort studies facilitated by the NCI Cohort Consortium, which aims to investigate risk factors for breast cancer in premenopausal women.

Other interests include cancer risk in relation to electromagnetic fields, risk factors for brain tumours, and cancer and mortality risks in patients with cytogenetic abnormalities.

She holds a Ph.D. in public health medicine, Master's degrees in radiation biology and medical statistics, and a B.Sc. in environmental health. Prior to joining The Institute of Cancer Research, she worked at the London School of Hygiene and Tropical Medicine and at Queen Mary University of London.



**Lynne Wilkens, Dr.P.H., M.S., University of Hawaii Cancer Center**

Dr. Lynne Wilkens received her Dr.P.H. in Biostatistics from the University of North Carolina at Chapel Hill. She is a Professor in the Epidemiology Program and the Director of the Biostatistics Shared Resource at the University of Hawaii Cancer Center (UHCC). Dr. Wilkens' research focuses on the estimation of cancer rates among the multiethnic, admixed populations of Hawaii and the broader Pacific, and reasons for the diversity in risk among racial/ethnic groups, in relation to lifestyle, genetic, and environmental factors. Of particular interest is

control of measurement error in lifestyle factors, such as diet and physical activity, and integration of data from diverse sources, such as questionnaires, medical records, biomarkers, and geospatial data. Dr. Wilkens has been a researcher in the Multiethnic Cohort (MEC) since its inception and is currently a Multiple Principal Investigator for the Multiethnic Cohort study. The prospective study, established in 1993, has followed over 215,000 Hawaii and Los Angeles residents of African American, Japanese, Latino, Native Hawaiian, and white ancestry. Dr. Wilkens has been involved in defining the MEC's study design, data structure, and analysis

approaches. The MEC has been successful at identifying differential associations of risk factors and cancer between the racial/ethnic group. For instance, stronger associations of light cigarette smoking with lung cancer were found among African Americans and Native Hawaiians, which was partially explained by genetic susceptibility. The strong association in Japanese Americans of adiposity with breast and colorectal cancer has been linked to the propensity for this low-BMI group to accumulate intra-abdominal fat. Dr. Wilkens is currently serving as the Chair on the steering committee of the National Cancer Institute Cohort Consortium.